Shots:

• The first patient has been dosed in global P-III AdvanTIG-302 trial evaluating ociperlimab + tislelizumab in 605 naïve patients with locally advanced- unresectable- or metastatic NSCLC whose tumors exhibit high PD-L1 expression and do not harbor EGFR-sensitizing mutations or ALK translocations across the US- Australia & other countries globally
• The 1EPs of the trial are PFS & OS in the ITT population & 2EPs include safety and other efficacy EPs
• Ociperlimab is currently being investigated in combination with tislelizumab in multiple ongoing trials while the company plans to explore the potential use of ociperlimab in additional settings & indications in its late-stage development program

  | Ref: Business Wire | Image: Business Times